What is the dosing regimen for amiodarone in the treatment of atrial fibrillation (afib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amiodarone Dosing for Atrial Fibrillation

For atrial fibrillation, start with an oral loading dose of 600-800 mg daily in divided doses until a total of 10 grams has been administered (typically 1-2 weeks), then reduce to a maintenance dose of 200 mg daily. 1

Oral Dosing Regimen

Loading Phase

  • Administer 600-800 mg daily in divided doses (typically 2-3 times per day) until reaching a cumulative total of 10 grams 1, 2
  • This loading phase typically requires 1-2 weeks depending on the daily dose used 2
  • Alternative higher loading doses of 800-1600 mg/day may be used but are associated with more side effects 1

Maintenance Phase

  • Reduce to 200 mg once daily after completing the 10-gram loading dose 1, 2
  • Some patients may require 200-400 mg daily for optimal rhythm control 1
  • Lower maintenance doses (200 mg daily or less) are associated with fewer side effects while maintaining efficacy 1

Intravenous Dosing (When Immediate Treatment Required)

Initial Loading

  • 150 mg IV over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours 1, 3
  • Target approximately 1000 mg over the first 24 hours 3

Maintenance Infusion

  • Continue at 0.5 mg/min (720 mg/24 hours) after the first 24 hours 3
  • Can be continued for 2-3 weeks regardless of age, renal function, or left ventricular function 3

Breakthrough Episodes

  • Administer 150 mg supplemental infusion over 10 minutes for breakthrough arrhythmias 3

Transitioning from IV to Oral

Begin oral amiodarone at 600-800 mg daily while continuing the IV infusion at 0.5 mg/min, particularly for patients who have received IV therapy for 1-3 weeks 2

  • Continue oral loading until the 10-gram total is reached, then transition to 200-400 mg daily maintenance 2
  • Monitor closely for bradycardia (occurs in 4.9% on IV, 1-3% on oral), hypotension (16% with IV), and AV block during the transition 2

Critical Monitoring Requirements

Cardiovascular Monitoring

  • Check ECG for QT prolongation, bradycardia, and heart block before and during therapy 1, 2
  • Monitor heart rate every 4-6 hours initially, then at least daily 2
  • Continuous telemetry for at least 24 hours after IV discontinuation 2

Drug Interactions Requiring Dose Adjustments

  • Reduce warfarin dose by 30-50% and check INR within 3-5 days, as amiodarone significantly increases INR 2
  • Reduce digoxin dose by 50% immediately, as amiodarone doubles digoxin levels 2
  • Reduce doses of beta-blockers and calcium channel blockers as amiodarone's rate-control effect develops 2

Efficacy Data

Amiodarone is more effective than class I agents or sotalol for maintaining sinus rhythm in atrial fibrillation. 1, 2

  • In the CTAF study, 69% of patients on amiodarone maintained sinus rhythm versus 39% on propafenone or sotalol over 16 months 1
  • In the AFFIRM study, 62% on amiodarone remained in sinus rhythm at 1 year compared to 23% on class I agents 1, 2
  • Median time to AF recurrence was 487 days with amiodarone versus 74 days with sotalol 2

Common Pitfalls and Safety Considerations

Adverse Effects to Monitor

  • Photosensitivity, pulmonary toxicity, polyneuropathy, GI upset, bradycardia, hepatic toxicity, thyroid dysfunction, and eye complications are potential long-term concerns 1
  • Torsades de pointes is rare with amiodarone compared to other antiarrhythmics 1
  • Approximately 18% of patients discontinue amiodarone due to side effects during long-term therapy 1

Administration Precautions for IV Formulation

  • Use concentrations ≤2 mg/mL for peripheral IV to minimize phlebitis risk; higher concentrations require central venous access 3
  • Must use volumetric infusion pump, not drop counters, as drop size reduction can cause up to 30% underdosing 3
  • Administer in glass or polyolefin bottles only; avoid evacuated glass containers 3

Patient Selection

  • Amiodarone is particularly appropriate for patients with left ventricular hypertrophy, heart failure, coronary artery disease, or previous MI due to low proarrhythmic risk in these populations 1
  • Chronic AF present for >1 year has lower success rates (57%) but still reasonable efficacy 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Amiodarone Oral to Intravenous Equivalency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Amiodarone for refractory atrial fibrillation.

The American journal of cardiology, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.